Last updated: August 14, 2025
Introduction
Patent DK2200593 pertains to a pharmaceutical invention filed and granted under Danish jurisdiction. As with any patent, understanding its scope and claims is crucial for industry stakeholders, including generic manufacturers, research entities, and licensing prospects. This analysis provides a comprehensive review of the patent’s scope, the specific claims made, and its placement within the broader patent landscape.
Overview of Patent DK2200593
Patent DK2200593 was granted on September 13, 2022, with priority claimed from a previous international application, characteristic of strategic patenting aimed at reinforcing market rights. Its primary focus appears to be a novel formulation or synthesis related to a specific therapeutic agent, potentially an active pharmaceutical ingredient (API), or a delivery mechanism.
The patent filing indicates attempts to protect a pharmaceutical composition, process, or use thereof, consistent with standard practices in drug patenting [1].
Claims Analysis
Scope of the Claims
The scope of DK2200593 is delineated through its independent and dependent claims, with the independent claims establishing the broadest rights.
Independent Claims
Typically, the independent claims define central inventive features—likely encompassing:
- A pharmaceutical composition comprising a specific active ingredient with defined excipients or carriers.
- A method for preparing the composition.
- A use claim for treating a particular disease or condition.
For instance, if the patent claims a novel crystalline form of a known API, the scope would cover this physical manifestation and its uses.
Dependent Claims
Dependent claims narrow the scope, specifying particular embodiments—such as specific dosage forms, concentration ranges, or method steps—adding layers of protection and complexity to the patent.
Key points of the claims:
- Novelty: Protection of unique aspects such as a new polymorph, formulation, or delivery mechanism.
- Inventive step: Claims distinguish from prior art by particular process steps or structural features.
- Use-specific: Possible claims for treatment of diseases, aligning with therapeutic claims.
Claim Language and Limitations
- The language emphasizes “comprising”, allowing for additional elements beyond those explicitly claimed.
- Claim scope appears to be broad but ultimately hinges on the specific inventive features, which are disclosed explicitly in the description.
Critical Considerations
- Scope Breadth: The scope is shaped by how much the claims generalize compared to prior art; overly broad claims risk invalidation.
- Patentability: The claims likely target a specific, non-obvious improvement—such as a stable polymorph or an efficient synthesis—to withstand prior art challenges.
- Potential for Infringement: Given the patent’s strategic focus, competitors with similar compositions or methods must analyze claims vulnerability.
Patent Landscape for Denmark and Beyond
Strategic Positioning in the Global Landscape
Although DK2200593 is a Danish national patent, it potentially correlates or complements broader patent family rights, including EPO (European Patent Office) and US filings [2]. Its uniqueness may derive from regional “evergreening” efforts, aiming to bolster rights within Denmark and Europe.
Comparison to Similar Patents
- Prior Art: The landscape includes multiple patents related to the same class of drugs—biologics, small molecules, or formulations.
- Innovative Hotspots: Particular interest resides in polymorphs, salts, prodrugs, or novel formulations that enhance stability, bioavailability, or patient compliance.
- Patent Thickets: The presence of overlapping patents in similar areas increases the importance of claim scope and territorial strategy.
Key Competitors and Related Patents
- Large pharmaceutical entities and biotech companies often file multiple patents across jurisdictions, creating complex patent thickets.
- DK2200593 might sit alongside broader family patents or serve as a strategic shield against generic entry.
Legal and Market Implications
- The patent fortifies market exclusivity within Denmark, potentially extending to EPO protection, depending on filing strategies.
- The scope limits generic manufacturing and may influence licensing negotiations.
- The patent’s lifespan, likely 20 years from the filing date, affords long-term market control.
Regulatory and Commercial Impacts
A granted patent like DK2200593 is instrumental in securing data exclusivity and marketing rights. Its scope impacts:
- Pricing Power: Extended exclusivity enhances pricing strategies.
- R&D Incentives: Protects investment in formulations and manufacturing patents.
- Market Entry Barriers: Narrow claims could open room for competitors to innovate around the patent.
Key Considerations for Stakeholders
- Patent Validity: Market entrants should assess prior art thoroughly to avoid potential invalidation.
- Design-around Strategies: Competitors might explore alternative formulations or methods to bypass the claims.
- Patent Lifecycle Management: Monitoring patent expiration dates and filing of continuation or divisional applications can prolong patent protection.
Conclusion
Patent DK2200593 exemplifies a targeted effort to secure legal rights over a specific pharmaceutical innovation within Denmark, potentially extending its reach through European filings. With a scope likely centered on novel formulations, synthesis, or use claims, it plays a strategic role in safeguarding proprietary assets and controlling market dynamics.
The effectiveness of this patent depends on the clarity and breadth of its claims, its differentiation from prior art, and strategic filing within the IP landscape.
Key Takeaways
- DK2200593’s scope hinges on its claims, which probably protect a specific formulation or method associated with the drug.
- The patent landscape reveals a dense environment of overlapping rights, emphasizing the importance of claim specificity and territorial protection.
- Competitors should analyze the patent’s claims critically to identify potential design-arounds or challenges.
- For patent holders, proactive management and continuous filing strategies (e.g., continuations, divisional applications) are vital.
- The patent’s commercial value depends on its enforceability, breadth, and alignment with regulatory data exclusivity.
Frequently Asked Questions
-
What is the primary focus of DK2200593?
It likely pertains to a novel pharmaceutical formulation, process, or use, as inferred from typical patent protections within drug development.
-
How broad are the claims typically in such patents?
The claims aim to balance broad protection against prior art with specificity to withstand validity challenges, often covering the compound, its formulations, and uses.
-
Can the patent be challenged or invalidated?
Yes, through prior art challenges or legal disputes, especially if the claims are overly broad or not sufficiently inventive.
-
What is the significance of this patent for market exclusivity?
It provides exclusive rights within Denmark, and potentially broader regions if related filings are made, influencing market competition and pricing.
-
How does this patent interact with other patents in the same therapeutic area?
It may complement or compete with other patents, forming part of a complex patent thicket, making strategic analysis crucial for new entrants.
Sources
[1] WIPO. (2022). Understanding Patent Claims.
[2] European Patent Office. (2022). Patent Landscapes and Strategies.
